US 11033533
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted A61KA61K31/421A61K45/06
Quick answer
US patent 11033533 ((2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid) held by Theravance Biopharma R&D IP, LLC expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/421, A61K45/06, A61K47/12, A61K9/4816